WFL 0.00% 0.3¢ wellfully limited

Ann: Pharmaceutical Clinical Study Commences, page-62

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 611 Posts.
    lightbulb Created with Sketch. 122
    Not much action on this clinical study...

    The clinical trials page hasn't been updated since 26/09/2017 (at which time there were 3 of 20 recruits);


    https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373049


    Interesting to see the professor has published this knee-related study though;

    http://www.oarsijournal.com/article/S1063-4584(17)31091-9/abstract

    In the acknowledgements;

    "The study was funded by an Investigator Initiated Study Programme grant from Merck Inc. The application was reviewed in line with the normal funding process. Merck Inc provided the drugs and an unrestricted grant to run the study but was not involved in data analysis, data interpretation, or in the preparation of the manuscript."

    (The study used an oral drug, not topical)


    Edit: May as well post the abstract here as well;

    Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial


    P. Moss, H.A.E. Benson, R. Will, A. Wright
    Objective

    Mounting evidence points to the heterogeneity of osteoarthritis (OA) pain, increasing the need for more comprehensive assessment of the efficacy of standard interventions. This study investigated whether 14 days of the selective Cox-2 inhibitor etoricoxib (60 mg/day) would modify self-report of pain intensity and quality, and physical measures of hyperalgesia and function in individuals with knee OA.
    Design

    This double-blind placebo-controlled trial included 80 community-recruited volunteers with painful knee OA (≥3/10 VAS), randomly allocated to Active or Placebo groups. Self-report measures of pain, stiffness, function Western Ontario and McMaster University Osteoarthritis Index (WOMAC) and pain quality (PainDETECT, Pain Quality Assessment Scale [PQAS]) and physical measures of locomotion and local (knee) and widespread (elbow) hyperalgesia were assessed at Days 0, 4 and 14. Repeated Measures ANOVA analysed group differences.
    Results

    Significant group × time interaction effects were found for all measures of pain (all p < 0.001), with WOMAC pain sub-score improving by 30.7% by Day 14 and index knee mechanical hyperalgesia improving by 32.6%, whilst Placebo group values worsened. Both self-report and physical tests of function improved (p < 0.001–p = 0.006): WOMAC-function by 28.4%, sit-to-stand and walk time by 13%, pain during locomotion tasks by 12.4–32.6%. Pain quality also significantly improved for the Active and declined for the Placebo group (p < 0.001): PainDETECT score reduced by 23.6% and PQAS paroxsysmal and surface sub-scores by 36.9% and 29.4%. There were also significant improvements in local cold hyperalgesia and widespread mechanical hyperalgesia (10–13.8%).
    Conclusion

    Just 14 days of etoricoxib significantly improves pain intensity and quality, function and local and widespread hyperalgesia, measured by both self-report and physical tests.
    Last edited by drmatt: Added abstract 19/12/17
 
watchlist Created with Sketch. Add WFL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.